These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 9389683

  • 1. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
    Zhao RC, McIvor RS, Griffin JD, Verfaillie CM.
    Blood; 1997 Dec 15; 90(12):4687-98. PubMed ID: 9389683
    [Abstract] [Full Text] [Related]

  • 2. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
    Zhao RC, Jiang Y, Verfaillie CM.
    Blood; 2001 Apr 15; 97(8):2406-12. PubMed ID: 11290604
    [Abstract] [Full Text] [Related]

  • 3. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.
    Takebe N, Zhao SC, Adhikari D, Mineishi S, Sadelain M, Hilton J, Colvin M, Banerjee D, Bertino JR.
    Mol Ther; 2001 Jan 15; 3(1):88-96. PubMed ID: 11162315
    [Abstract] [Full Text] [Related]

  • 4. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X, Ren R.
    Blood; 1998 Nov 15; 92(10):3829-40. PubMed ID: 9808576
    [Abstract] [Full Text] [Related]

  • 5. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors.
    Traycoff CM, Srour EF, Dutt P, Fan Y, Cornetta K.
    Leukemia; 1997 Jan 15; 11(1):159-67. PubMed ID: 9001433
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 15; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 8. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.
    Blood; 1996 Oct 15; 88(8):3091-100. PubMed ID: 8874208
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R, Verfaillie CM.
    Blood; 1998 May 01; 91(9):3414-22. PubMed ID: 9558400
    [Abstract] [Full Text] [Related]

  • 11. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB.
    Blood; 1996 Jun 01; 87(11):4770-9. PubMed ID: 8639848
    [Abstract] [Full Text] [Related]

  • 12. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G, Hochhaus A, Schultheis B, Hehlmann R.
    J Cancer Res Clin Oncol; 1998 Jun 01; 124(12):643-60. PubMed ID: 9879825
    [Abstract] [Full Text] [Related]

  • 13. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan 01; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 14. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette.
    Dugray A, Geay JF, Foudi A, Bonnet ML, Vainchenker W, Wendling F, Louache F, Turhan AG.
    Leukemia; 2001 Oct 01; 15(10):1658-62. PubMed ID: 11587226
    [Abstract] [Full Text] [Related]

  • 15. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
    Chu S, Li L, Singh H, Bhatia R.
    Cancer Res; 2007 Jul 15; 67(14):7045-53. PubMed ID: 17638918
    [Abstract] [Full Text] [Related]

  • 16. Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
    Winter SS, Greene JM, McConnell TS, Willman CL.
    Leukemia; 1999 Dec 15; 13(12):2007-11. PubMed ID: 10602422
    [Abstract] [Full Text] [Related]

  • 17. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V.
    Blood; 1999 Jun 01; 93(11):3973-82. PubMed ID: 10339507
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.
    Takebe N, Xu LC, MacKenzie KL, Bertino JR, Moore MA.
    Cancer Gene Ther; 2002 Mar 01; 9(3):308-20. PubMed ID: 11896448
    [Abstract] [Full Text] [Related]

  • 20. Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: a comparison of methotrexate resistance.
    Braun SE, McIvor RS, Davidson AS, Hanna M, Traycoff CM, Berebetsky DA, Gonin R, Broxmeyer HE, Cornetta K.
    Cancer Gene Ther; 1997 Mar 01; 4(1):26-32. PubMed ID: 9012448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.